SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 11 2025
0mins
Should l Buy SOPH?
Source: PRnewswire
Collaboration Announcement: Complete Genomics and SOPHiA GENETICS have partnered to co-market MSK-ACCESS® and MSK-IMPACT® using SOPHiA DDM™ on Complete Genomics' DNBSEQ-T1+ sequencing platform, aiming to enhance access to precision oncology testing globally.
Integrated Workflow: The collaboration will provide an integrated sample-to-report workflow for laboratories, combining MSK's validated assays, SOPHiA GENETICS' analytics, and Complete Genomics' sequencing technology to improve cancer genomic profiling.
Technological Advancements: The DNBSEQ-T1+ platform offers high accuracy and flexibility, allowing laboratories to run multiple tumor-normal sample pairs efficiently, while SOPHiA DDM™ enhances data analysis through AI.
Market Impact: This partnership is expected to facilitate the adoption of precision oncology solutions in clinical laboratories and cancer centers, providing a cost-effective path for comprehensive genomic profiling in research.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SOPH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SOPH
Wall Street analysts forecast SOPH stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.460
Low
7.00
Averages
7.00
High
7.00
Current: 4.460
Low
7.00
Averages
7.00
High
7.00
About SOPH
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SOPHiA GENETICS (SOPH) Q4 2025 Earnings Transcript
See More
SOPHiA Genetics Q4 Earnings Report Analysis
- Earnings Performance: SOPHiA Genetics reported a Q4 GAAP EPS of -$0.28, missing the expected -$0.26, indicating ongoing challenges in profitability that may affect investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $21.7 million, a 22.4% year-over-year increase, surpassing market expectations of $21.6 million, suggesting strong market demand in genomics that could lay the groundwork for future growth.
- Market Reaction: Despite the revenue beat, the EPS miss may pressure the stock price in the short term, prompting investors to monitor the company's future profitability improvement strategies to assess its long-term investment value.
- Strategic Outlook: SOPHiA Genetics needs to demonstrate stronger profitability and sustained revenue growth in upcoming reports to bolster market confidence and attract more investors, particularly in the highly competitive genomics market.
See More
SOPHiA GENETICS Reports Strong Q4 and FY 2025 Results
- Significant Revenue Growth: In Q4 2025, SOPHiA GENETICS reported a 22% year-over-year revenue increase, with a full-year growth of 19%, indicating robust momentum in the precision medicine sector that is expected to enhance shareholder value further.
- Margin Improvement: The adjusted gross margin for 2025 expanded by 140 basis points to 74.2%, even as total terabytes processed by the platform increased by 40%, demonstrating significant progress in cost control and operational efficiency.
- Customer Base Expansion: The company signed 124 new customers in 2025 and partnered with two major integrated health systems in the U.S., expected to add 60,000 analyses annually, laying a solid foundation for future revenue growth.
- Positive Future Outlook: SOPHiA GENETICS anticipates continued execution of growth strategies in the U.S. market in 2026, expansion of its Liquid Biopsy application MSK-ACCESS®, and renewed momentum in its BioPharma business, showcasing strong market potential and sustainable growth capabilities.
See More
SOPHiA GENETICS Expands U.S. Healthcare Network with Major Partnerships
- Partnership Expansion: SOPHiA GENETICS has partnered with two major U.S. healthcare systems to provide genomic testing for up to 60,000 patients annually, significantly enhancing diagnostic speed and personalized care for hereditary cancers and rare diseases.
- Technology Application Upgrade: The collaboration will leverage the SOPHiA DDM™ platform for comprehensive exome analysis of over 20,000 genes, optimizing laboratory workflows to accelerate testing turnaround times and reduce operational costs, thereby fostering internal research and innovation.
- Market Demand Response: This partnership highlights the growing need for AI-driven genomic solutions, as SOPHiA GENETICS integrates advanced bioinformatics and the collective knowledge of a global community to help healthcare institutions unlock deeper clinical insights.
- Future Development Potential: The collaboration provides both organizations with a scalable foundation to support future expansion of AI-driven precision medicine, expected to serve nearly one million cancer and rare disorder patients, further solidifying SOPHiA GENETICS' influence in the U.S. market.
See More
SOPHiA GENETICS Projects 20%-22% Revenue Growth in 2026 and Appoints New CEO
- 2025 Financial Performance: SOPHiA GENETICS anticipates a revenue growth of 20%-22% for Q4 and the full year 2025, indicating strong performance in the AI-driven precision medicine sector and laying a solid foundation for future growth.
- Management Transition: The company announced that Ross Muken will succeed Jurgi Camblong as CEO on July 1, 2026, with Camblong transitioning to Executive Chairman, ensuring continuity and stability in the company's strategic direction.
- Market Opportunities: SOPHiA GENETICS plans to leverage its leading liquid biopsy application MSK-ACCESS® and potential opportunities in the U.S. market to further drive business growth in 2026, demonstrating the company's keen insight into market demands.
- Strategic Investment: During Muken's tenure, he successfully transformed the commercial organization and accelerated sales processes, and he is expected to continue leveraging his extensive experience to enhance the company's global impact and market share.
See More
SOPHiA GENETICS Reports Strong Q4 2025 Performance, Projects 20-22% Revenue Growth for 2026
- Strong 2025 Performance: SOPHiA GENETICS reported robust Q4 results in 2025, exceeding new business booking targets and laying the groundwork for future growth, with projected revenue growth of 20-22% in 2026, highlighting the company's sustained leadership in precision medicine.
- Executive Transition Plan: The company announced that Ross Muken will succeed co-founder Jurgi Camblong as CEO on July 1, 2026, while Camblong transitions to Executive Chairman, ensuring continuity and stability in the company's strategic direction.
- Market Opportunities and Growth Catalysts: SOPHiA GENETICS aims to leverage its leading Liquid Biopsy application MSK-ACCESS® and valuable opportunities in the U.S. market to reinvigorate its BioPharma business, which is expected to significantly enhance operational leverage and financial position.
- Strategic Leadership Adjustments: Kevin Puylaert has been appointed Chief Sales Officer, tasked with driving sales growth in the EMEA region, further solidifying the company's competitive edge in the global market.
See More
SOPHiA GENETICS (SOPH) Q4 2025 Earnings Transcript
See More
SOPHiA Genetics Q4 Earnings Report Analysis
- Earnings Performance: SOPHiA Genetics reported a Q4 GAAP EPS of -$0.28, missing the expected -$0.26, indicating ongoing challenges in profitability that may affect investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $21.7 million, a 22.4% year-over-year increase, surpassing market expectations of $21.6 million, suggesting strong market demand in genomics that could lay the groundwork for future growth.
- Market Reaction: Despite the revenue beat, the EPS miss may pressure the stock price in the short term, prompting investors to monitor the company's future profitability improvement strategies to assess its long-term investment value.
- Strategic Outlook: SOPHiA Genetics needs to demonstrate stronger profitability and sustained revenue growth in upcoming reports to bolster market confidence and attract more investors, particularly in the highly competitive genomics market.
See More
SOPHiA GENETICS Reports Strong Q4 and FY 2025 Results
- Significant Revenue Growth: In Q4 2025, SOPHiA GENETICS reported a 22% year-over-year revenue increase, with a full-year growth of 19%, indicating robust momentum in the precision medicine sector that is expected to enhance shareholder value further.
- Margin Improvement: The adjusted gross margin for 2025 expanded by 140 basis points to 74.2%, even as total terabytes processed by the platform increased by 40%, demonstrating significant progress in cost control and operational efficiency.
- Customer Base Expansion: The company signed 124 new customers in 2025 and partnered with two major integrated health systems in the U.S., expected to add 60,000 analyses annually, laying a solid foundation for future revenue growth.
- Positive Future Outlook: SOPHiA GENETICS anticipates continued execution of growth strategies in the U.S. market in 2026, expansion of its Liquid Biopsy application MSK-ACCESS®, and renewed momentum in its BioPharma business, showcasing strong market potential and sustainable growth capabilities.
See More
SOPHiA GENETICS Expands U.S. Healthcare Network with Major Partnerships
- Partnership Expansion: SOPHiA GENETICS has partnered with two major U.S. healthcare systems to provide genomic testing for up to 60,000 patients annually, significantly enhancing diagnostic speed and personalized care for hereditary cancers and rare diseases.
- Technology Application Upgrade: The collaboration will leverage the SOPHiA DDM™ platform for comprehensive exome analysis of over 20,000 genes, optimizing laboratory workflows to accelerate testing turnaround times and reduce operational costs, thereby fostering internal research and innovation.
- Market Demand Response: This partnership highlights the growing need for AI-driven genomic solutions, as SOPHiA GENETICS integrates advanced bioinformatics and the collective knowledge of a global community to help healthcare institutions unlock deeper clinical insights.
- Future Development Potential: The collaboration provides both organizations with a scalable foundation to support future expansion of AI-driven precision medicine, expected to serve nearly one million cancer and rare disorder patients, further solidifying SOPHiA GENETICS' influence in the U.S. market.
See More
SOPHiA GENETICS Projects 20%-22% Revenue Growth in 2026 and Appoints New CEO
- 2025 Financial Performance: SOPHiA GENETICS anticipates a revenue growth of 20%-22% for Q4 and the full year 2025, indicating strong performance in the AI-driven precision medicine sector and laying a solid foundation for future growth.
- Management Transition: The company announced that Ross Muken will succeed Jurgi Camblong as CEO on July 1, 2026, with Camblong transitioning to Executive Chairman, ensuring continuity and stability in the company's strategic direction.
- Market Opportunities: SOPHiA GENETICS plans to leverage its leading liquid biopsy application MSK-ACCESS® and potential opportunities in the U.S. market to further drive business growth in 2026, demonstrating the company's keen insight into market demands.
- Strategic Investment: During Muken's tenure, he successfully transformed the commercial organization and accelerated sales processes, and he is expected to continue leveraging his extensive experience to enhance the company's global impact and market share.
See More
SOPHiA GENETICS Reports Strong Q4 2025 Performance, Projects 20-22% Revenue Growth for 2026
- Strong 2025 Performance: SOPHiA GENETICS reported robust Q4 results in 2025, exceeding new business booking targets and laying the groundwork for future growth, with projected revenue growth of 20-22% in 2026, highlighting the company's sustained leadership in precision medicine.
- Executive Transition Plan: The company announced that Ross Muken will succeed co-founder Jurgi Camblong as CEO on July 1, 2026, while Camblong transitions to Executive Chairman, ensuring continuity and stability in the company's strategic direction.
- Market Opportunities and Growth Catalysts: SOPHiA GENETICS aims to leverage its leading Liquid Biopsy application MSK-ACCESS® and valuable opportunities in the U.S. market to reinvigorate its BioPharma business, which is expected to significantly enhance operational leverage and financial position.
- Strategic Leadership Adjustments: Kevin Puylaert has been appointed Chief Sales Officer, tasked with driving sales growth in the EMEA region, further solidifying the company's competitive edge in the global market.
See More
